The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Plaquenil: From Malaria Treatment to Managing Lupus, RA

Plaquenil: From Malaria Treatment to Managing Lupus, RA

May 15, 2015 • By Charles Radis, DO

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Plaquenil is a mainstay of treatment for inflammatory arthritis and skin symptoms.

Plaquenil is a mainstay of treatment for inflammatory arthritis and skin symptoms.
Image Credit: Alice Day/shutterstock.com

In 1984, I wrote my first prescription for the antimalarial drug, hydroxychloroquine (Plaquenil), for a 28-year-old woman with SLE. She was considerably overweight, with inflammatory arthritis and a photosensitive rash, and I worried that oral corticosteroids would tip her over into diabetes. I presented the case to my attending, Steven Malawista, MD, at the Yale New Haven Medical Center (Conn.) where I was a visiting internal medicine resident, and to my relief, he agreed with my plan.

You Might Also Like
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Immunosuppressive Treatment for Lupus in the Next Decade
Explore This Issue
May 2015
Also By This Author
  • Diffuse Scleroderma: A 1991 Case Through the Lens of Today

But at that time, in reviewing potential side effects, I had to scare the “bajeezus” out of my patient: “Plaquenil is usually very safe,” I told her, “but it can damage your retina, and we need to obtain a baseline eye exam and then monitor your eyes every six months for as long as you are on the drug.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

I can still remember her pointing an accusing finger at my nose and saying, “You mean to tell me that because I have this ugly rash and some aches and pains, you’re going to give me a medicine that might make me go blind?”

“Well, ugh, no, I mean we need to be cautious. Just a minute. Let me get my attending, and he can talk to you.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Luckily, Dr. Malawista was able to convince our patient to take the prescription. After three months, it worked; her rash and inflammatory arthritis resolved. She didn’t go blind. Actually, over the ensuing 31 years, none of my patients have suffered visual loss on Plaquenil. That is a wonderful story in itself: How many of our medications have stood the test of time as effective medications and are safer than originally believed? And how did we make the leap from treatment of malaria to the recognition of Plaquenil’s value in the management of lupus and rheumatoid arthritis?

In the treatment of SLE, [Plaquenil is] widely regarded as a cornerstone drug in the management of skin & arthritis symptoms.

History of Antimalarials

The history of antimalarials dates back to the 1630s in Peru, where, in all likelihood, malaria was not endemic, and an extract from the “fever tree,” which grew on the eastern slopes of the Andes. Antonio de Calancha, an Augustinian monk, was the European first credited with describing the medicinal effects of the fever tree, “whose bark, of the color of cinnamon, made into powder amounting to the weight of two small silver coins and given as a beverage, cures the fevers and tertiana; it has produced miraculous results in Lima.”1

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis, SLE (Lupus) Tagged With: anti-malarial, drug, Lupus, Plaquenil, Rheumatoid arthritisIssue: May 2015

You Might Also Like:
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Immunosuppressive Treatment for Lupus in the Next Decade
  • Updates on Managing Lupus Complications

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.